Search

In the present study, whether there is an effect of a delay or not is an interesting point for further study. Regarding the present report on mortality, there are many confounding factors. In a different COVID-19 case, severity might be different.

References 1 Lim PN, Wylie G. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. COVID-19 vaccination and exanthema-like eruption Dear Editor, We read with interest the paper by Lim and Wylie1 published recently in I Clinical and Experimental Dermatology i , in which they proposed a possible association between an exanthema-like eruption of the skin and the administration of the ChAdOx1 nCoV-19 (AstraZeneca-Oxford) COVID-19 vaccine. [Extracted from the article]

Null.

How to cite this article: Mungmunpuntipantip R, Wiwanitkit V. ChatGPT in Trauma Triage. Indian J Crit Care Med 2024;28(6):617., Competing Interests: Source of support: Nil Conflict of interest: None, (Copyright © 2024; The Author(s).)

Vector-borne disease is an important public health problem. This disease is common in tropical areas and affects millions of people. The control and management of disease is an important consideration. Effective treatment is important in management of patients infected with vector-borne disease. A common problem in therapeutic management of the patient is the lack of an effective drug. Therefore, it is necessary to find a new effective drug for managing vector-borne disease. To search for a new drug, new technologies are applicable. Bioinformatics technologies are useful in new drug search. Application of the bioinformatics technologies in new anti-vector-borne disease drug search is interesting. In this review, the author briefly discusses the use of bioinformatics technology in searching for natural products in vector-borne disease management. Concepts and examples of some important diseases are presented., Competing Interests: No conflict of interest was declared by the authors., (© Copyright 2024 by Istanbul Provincial Directorate of Health.)

Background: The new COVID-19 variant outbreak is the present global public health problem. The omicron variant of SARS-CoV-2 has several subvariants and causes outbreaks worldwide. Because of the increasing genetic heterogeneity of SARS-CoV-2, it is expected that using COVID-19 immunization to prevent and control disease will be problematic., Aim: The aim of the study was to study neutralization of antibody titer and change in 50% protection after the third dose of the COVID-19 vaccine., Materials and Methods: In this report, the authors determine the expected neutralization antibody titer against omicron subvariants and the change in 50% protection against infection after the third dose of the immunization., Results: The change due to subvariant B.4 or B.5 is substantially higher than that due to the other subvariants. The efficacy of using viral vector vaccine boosters is questionable since viral vector COVID-19 boosters fail to generate enough antibodies to achieve the mean convalescent plasma level., Conclusion: Higher antibody levels than the typical convalescent level and that needed for half protective property are still possible with the mRNA vaccine booster shot. In addition, compared to the half-dose regimen, the full-dose regimen produces a higher antibody level. As a booster shot, the mRNA COVID-19 vaccine is recommended., (Copyright © 2024 Copyright: © 2024 Indian Journal of Pharmacology.)

Competing Interests: There are no conflicts of interest.

Competing Interests: There are no conflicts of interest.

Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Competing Interests: There are no conflicts of interest.